michigan glp-1 diarrhea lawsuit Ozempic Lawsuit [May 2026 Update] Ozempic GLP-1 Lawsuit [2026]: Gastroparesis

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

The most common side-effects of acarbose are mild-to-moderate gastrointestinal complaints that subside as treatment continues

Challenges with GLP-1 Therapy: Many users experience energy dips, muscle loss, and nutrient deficiencies while on GLP-1 therapies like semaglutide

Were looking forward to catching up with industry leaders, researchers, and sponsors to discuss how we can drive progress together

Supergut, a leader in gut-health innovation, announced the launch of three new flavors of its GLP-1 Booster: Blood Orange, Raspberry Lemon and Watermelon Lime.

Fast-Acting Liquid with Flexible Use: Delivered in a convenient liquid form for fast absorption and ease of use, each serving provides targeted nutrients to support digestion, satiety, metabolism, and weight management